Central Asia Drug Action Programme – Phase 6 (CADAP 6)

Programme description

Title: Central Asia Drug Action Programme
Commissioned by: German Federal Ministry for Economic Cooperation and Development (BMZ)
Countries: Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan and Uzbekistan
Lead executing agency: Ministries of Internal Affairs and Health, Central Asia
Overall term: 2015 to 2018

There is a strong link between drug trafficking and the spread of crime, corruption, substance abuse and HIV infection in the Central Asian States – with serious implications for their legal, political, economic, and social stability. Heroin dependency amongst registered drug users in this region is high (between 50% - 80% depending on the country). Injecting drug use ranks as one of the main causes of HIV and other blood-borne infections. Although these states have done a great deal to raise awareness about the risk of infection from sharing needles and other drug injecting paraphernalia, more still needs to be done to make people aware of what they can do to prevent HIV infection (UNODC, 2015).

CADAP, which was initially launched in 2001, is assisting the Central Asian governments to implement policies and measures designed to reduce demand for illegal drugs.

The Central Asian States’ capacity to deal with the drug phenomenon in a comprehensive, integrative and sustainable manner is improved. This benefits the people in Central Asia, in particular policymakers, drug experts, prison and hospital staff, media professionals, teachers, drug users, prisoners and young people.

Having entered its sixth phase in April 2015, CADAP is continuing to strengthen the capacity of its five Central Asian partner countries, empowering them to design and implement appropriate drug policies, including a comprehensive, integrative and sustainable approach for reducing drug demand and supply.

CADAP 6 continues to build on the results attained in previous phases by investing in capacity building and professional skills upgrading at drug-related ministries, state agencies, rehabilitation centres and amongst other key stakeholders. At the same time, it is promoting and further advocating the mainstreaming and application of European best practices. GIZ took charge of CADAP coordination and steering in 2010.

All programme activities focus both on national and regional capacity building. Activities range from policy advice and technical assistance to monitoring the drugs situation, prevention, drug treatment and harm reduction services.

CADAP is being financed by the European Union and implemented by a consortium of EU institutions: Trimbos Institute (Netherlands), ResAd (Czech Republic), National Bureau for Drug Prevention (Poland) and the Frankfurt University of Applied Sciences (Germany).

CADAP 6 consists of four components: National drug strategies, national focal points, prevention, and treatment.


Ernest Robelló